Outcomes for COPD pharmacological trials: from lung function to biomarkers.
The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.
Cazzola
M
M
Unit of Respiratory Diseases, Dept of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. mario.cazzola@uniroma2.it
MacNee
W
W
Martinez
F J
FJ
Rabe
K F
KF
Franciosi
L G
LG
Barnes
P J
PJ
Brusasco
V
V
Burge
P S
PS
Calverley
P M A
PM
Celli
B R
BR
Jones
P W
PW
Mahler
D A
DA
Make
B
B
Miravitlles
M
M
Page
C P
CP
Palange
P
P
Parr
D
D
Pistolesi
M
M
Rennard
S I
SI
Rutten-van Mölken
M P
MP
Stockley
R
R
Sullivan
S D
SD
Wedzicha
J A
JA
Wouters
E F
EF
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D026683:Advisory Committees; D015415:Biomarkers / Q000097:blood*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011379:Prognosis; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D012129:Respiratory Function Tests; D018570:Risk Assessment; D012955:Societies, Medical; D016019:Survival Analysis; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D015415:Biomarkers; D001993:Bronchodilator Agents